Clinical Trial Update: A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial results for CORLUX (mifepristone) in endogenous Cushing's syndrome, with the study completed and results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Syndrome

Drugs mentioned

• CORLUX (mifepristone)

Snippet

Sponsor: Corcept Therapeutics | Conditions: Cushing's Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2012-05-28